The FDA has approved foscarbidopa and foslevodopa for 24-hour continuous subcutaneous infusion to treat motor fluctuations in adults with advanced Parkinson’s disease. This new non-surgical regimen provides continuous delivery of levodopa throughout the day. Studies have shown superior improvement in motor fluctuations with the continuous infusion compared to oral medications. The most common adverse reactions were non-serious and mild or moderate in severity. Medicare coverage for this treatment is expected in the second half of 2025. Overall, the approval of foscarbidopa and foslevodopa provides a new option for patients with advanced Parkinson’s disease who experience motor fluctuations.
Source link
FDA OKs Novel Levodopa-Based Regimen for Parkinson’s
